Literature DB >> 23197892

Nutritional support teams increase percutaneous endoscopic gastrostomy uptake in motor neuron disease.

Lin Zhang1, Leanne Sanders, Robert J L Fraser.   

Abstract

AIM: To examine factors influencing percutaneous endoscopic gastrostomy (PEG) uptake and outcomes in motor neuron disease (MND) in a tertiary care centre.
METHODS: Case notes from all patients with a confirmed diagnosis of MND who had attended the clinic at the Repatriation General Hospital between January 2007 and January 2011 and who had since died, were audited. Data were extracted for demographics (age and gender), disease characteristics (date of onset, bulbar or peripheral predominance, complications), date and nature of discussion of gastrostomy insertion, nutritional status [weight measurements, body mass index (BMI)], date of gastrostomy insertion and subsequent progress (duration of survival) and quality of life (QoL) [Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)]. In addition, the type of clinician initiating the discussion regarding gastrostomy was recorded as Nutritional Support Team (involved in providing nutrition input viz Gastroenterologist, Speech Pathologist, Dietitian) and other (involved in non-nutritional aspects of patient care). Factors affecting placement and outcomes including length of survival, change in weight and QoL were determined.
RESULTS: Case records were available for all 86 patients (49 men, mean age at diagnosis 66.4 years). Thirty-eight patients had bulbar symptoms and 48 had peripheral disease as their presenting feature. Sixty-six patients reported dysphagia. Thirty-one patients had undergone gastrostomy insertion. The major indications for PEG placement were dysphagia and weight loss. Nine patients required immediate full feeding, whereas 17 patients initially used the gastrostomy to supplement oral intake, 4 for medication administration and 1 for hydration. Initially the PEG regime met 73% ± 31% of the estimated total energy requirements, increasing to 87% ± 32% prior to death. There was stabilization of weight in patients undergoing gastrostomy [BMI at 3 mo (22.6 ± 2.2 kg/m(2)) and 6 mo (22.5 ± 2.0 kg/m(2)) after PEG placement compared to weight at the time of the procedure (22.5 ± 3.0 kg/m(2))]. However, weight loss recurred in the terminal stages of the illness. There was a strong trend for longer survival from diagnosis among MND in PEG recipients with limb onset presentation compared to similar patients who did not undergo the procedure (P = 0.063). Initial discussions regarding PEG insertion occurred earlier after diagnosis when seen by nutrition support team (NST) clinicians compared to other clinicians. (5.4 ± 7.0 mo vs 11.9 ± 13.4 mo, P = 0.028). There was a significant increase in PEG uptake (56% vs 24%, P = 0.011) if PEG discussions were initiated by the NST staff compared to other clinicians. There was no change in the ALSFRS-R score in patients who underwent PEG (pre 34.1 ± 8.6 vs post 34.8 ± 7.4), although in non-PEG recipients there was a non-significant fall in this score (33.7 ± 7.9 vs 31.6 ± 8.8). Four patients died within one month of the procedure, 4 developed bacterial site infection requiring antibiotics and 1 required endoscopic therapy for gastric bleeding. Less serious complications attributed to the procedure included persistent gastrostomy site discomfort, poor appetite, altered bowel function and bloating.
CONCLUSION: Initial discussion with NST clinicians increases PEG uptake in MND. Gastrostomy stabilizes patient weight but weight loss recurs with advancing disease.

Entities:  

Keywords:  Motor neuron disease; Multidisciplinary management; Nutrition support team; Percutaneous endoscopic gastrostomy; Survival

Mesh:

Year:  2012        PMID: 23197892      PMCID: PMC3508641          DOI: 10.3748/wjg.v18.i44.6461

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study Group.

Authors:  A Chiò; E Finocchiaro; P Meineri; E Bottacchi; D Schiffer
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

Review 2.  Symptomatic treatment of respiratory and nutritional failure in amyotrophic lateral sclerosis.

Authors:  O Hardiman
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

Review 3.  The management of motor neurone disease.

Authors:  P N Leigh; S Abrahams; A Al-Chalabi; M-A Ampong; L H Goldstein; J Johnson; R Lyall; J Moxham; N Mustfa; A Rio; C Shaw; E Willey
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

4.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Authors:  J M Cedarbaum; N Stambler; E Malta; C Fuller; D Hilt; B Thurmond; A Nakanishi
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

5.  Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis.

Authors:  L Mazzini; T Corrà; M Zaccala; G Mora; M Del Piano; M Galante
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

Review 6.  Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Hans Dieter Katzberg; Michael Benatar
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

7.  Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease--a record linkage study from the Scottish Motor Neurone Disease Register.

Authors:  Raeburn B Forbes; Shuna Colville; Robert J Swingler
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

8.  Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction.

Authors:  H Mitsumoto; M Davidson; D Moore; N Gad; M Brandis; S Ringel; J Rosenfeld; J M Shefner; M J Strong; R Sufit; F A Anderson
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2003-09

9.  Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000.

Authors:  B J Traynor; M Alexander; B Corr; E Frost; O Hardiman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

10.  Longitudinal analysis of progression of dysphagia in amyotrophic lateral sclerosis.

Authors:  Ryuzaburo Higo; Niro Tayama; Takaharu Nito
Journal:  Auris Nasus Larynx       Date:  2004-09       Impact factor: 1.863

View more
  3 in total

1.  Staging model for amyotrophic lateral sclerosis in Singapore.

Authors:  Yuan Teck Tay; Josiah Y H Chai; Kamilah Bte Shekh Jabin; Kexin Ang
Journal:  Singapore Med J       Date:  2022-07       Impact factor: 3.331

2.  Gastrostomy uptake in motor neurone disease: a mixed-methods study of patients' decision making.

Authors:  Julie Labra; Anne Hogden; Emma Power; Natalie James; Victoria M Flood
Journal:  BMJ Open       Date:  2020-02-25       Impact factor: 2.692

3.  Retrospective longitudinal study of ALS in Cyprus: Clinical characteristics, management and survival.

Authors:  Christiana A Demetriou; Petros M Hadjivasiliou; Kleopas A Kleopa; Yiolanda P Christou; Eleni Leonidou; Theodoros Kyriakides; Eleni Zamba-Papanicolaou
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.